What’s Next for MyoKardia, Inc. (MYOK) After Today’s Big Increase?

March 14, 2018 - By marketbeat

The stock of MyoKardia, Inc. (NASDAQ:MYOK) is a huge mover today! The stock increased 6.82% or $3.4 during the last trading session, reaching $53.25. About 726,743 shares traded or 71.06% up from the average. MyoKardia, Inc. (NASDAQ:MYOK) has risen 11.16% since March 14, 2017 and is uptrending. It has underperformed by 5.54% the S&P500.
The move comes after 7 months positive chart setup for the $1.91B company. It was reported on Mar, 14 by Barchart.com. We have $56.98 PT which if reached, will make NASDAQ:MYOK worth $133.91 million more.

Analysts await MyoKardia, Inc. (NASDAQ:MYOK) to report earnings on May, 8. They expect $-0.32 earnings per share, up 13.51 % or $0.05 from last year’s $-0.37 per share. After $-0.21 actual earnings per share reported by MyoKardia, Inc. for the previous quarter, Wall Street now forecasts 52.38 % negative EPS growth.

MyoKardia, Inc. (NASDAQ:MYOK) Ratings Coverage

Among 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MyoKardia had 5 analyst reports since November 23, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, December 4 by Wells Fargo. The firm earned “Outperform” rating on Monday, November 23 by Wedbush. On Monday, November 23 the stock rating was initiated by Cowen & Co with “Outperform”. The firm has “Outperform” rating by Credit Suisse given on Monday, November 23. The firm has “Outperform” rating given on Wednesday, July 20 by BMO Capital Markets.

More recent MyoKardia, Inc. (NASDAQ:MYOK) news were published by: Globenewswire.com which released: “MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results” on March 08, 2018. Also Globenewswire.com published the news titled: “MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in …” on February 14, 2018. Globenewswire.com‘s news article titled: “MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER …” with publication date: March 08, 2018 was also an interesting one.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. The company has market cap of $1.91 billion. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy . It currently has negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: